Nerve growth factor and methods of use thereof for neurodevelopmental disabilities associated with neonatal hypoxic-ischemic encephalopathy
AssigneeDompé Farmaceutici S.P.A.
InventorsAndrea Aramini, Laura Brandolini, Serena Boccella, Rubina Novelli
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to nerve growth factor (NGF) for use in the prevention or treatment of neurodevelopmental disabilities associated with neonatal hypoxic-ischemic encephalopathy in a subject, wherein the NGF is administered intranasally to the subject.
Claims23
A method of treating cerebral palsy associated with neonatal hypoxic-ischemic encephalopathy in a human subject in need thereof, the method comprising administering a therapeutically effective amount of nerve growth factor (NGF) intranasally to the subject only subsequent to a neonatal hypoxic-ischemic event, wherein the NGF comprises SEQ ID NO:
- 1.
A method of reducing likelihood or reducing severity of occurrence of cerebral palsy associated with neonatal hypoxic-ischemic encephalopathy in a human subject in need thereof, the method comprising administering a therapeutically effective amount of nerve growth factor (NGF) intranasally to the subject only subsequent to a neonatal hypoxic-ischemic event, wherein the NGF comprises SEQ ID NO:1, wherein the reducing likelihood or reducing severity of occurrence of cerebral palsy associated with neonatal hypoxic-ischemic encephalopathy is compared to a subject who has not received NGF.
Dependencies are inferred from the claim text.